Murine myeloid leukemia: in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes.
Parenteral administration of sericystatin A, an intracellular leukocyte inhibitor of the proinsulin-splitting enzyme cathepsin B, prolongs the mean survival time of mice with insulin-dependent myeloid leukemia. Sericystatin A reduces the supranormal blood levels of substances detectable by insulin-specific radioimmunoassay in these animals; this effect is abolished by concomitant insulin administration. It is concluded that sericystatin A reduces tumor proliferation indirectly, i.e. by reducing circulating insulin levels.
D000818:Animals; D002478:Cells, Cultured; D055312:Cystatin A; D015891:Cystatins; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011506:Proteins / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D013154:Spleen / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism
C501463:Csta1 protein, mouse; D055312:Cystatin A; D015891:Cystatins; D007328:Insulin; D011480:Protease Inhibitors; D011506:Proteins; D013936:Thymidine